Veracyte (NASDAQ:VCYT) Sets New 1-Year High – Here’s What Happened

17 Jun 2026, 08:11 by Tristan Rich · The Markets Daily

Veracyte, Inc. (NASDAQ:VCYT – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $52.45 and last traded at $50.92, with a volume of 1769979 shares trading hands. The stock had previously closed at $49.15.

Analyst Ratings Changes

Several research analysts have commented on the company. Guggenheim cut their target price on Veracyte from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Needham & Company LLC upped their price target on Veracyte from $48.00 to $57.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Weiss Ratings reissued a “hold (c)” rating on shares of Veracyte in a report on Friday, March 27th. Morgan Stanley cut their price objective on shares of Veracyte from $48.00 to $37.00 and set an “underweight” rating for the company in a research report on Thursday, March 5th. Finally, Jefferies Financial Group began coverage on shares of Veracyte in a report on Monday, April 13th. They set a “buy” rating and a $45.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $47.57.

Check Out Our Latest Research Report on Veracyte

Veracyte Stock Up 3.6%

The company has a 50-day moving average of $40.14 and a 200 day moving average of $39.30. The firm has a market capitalization of $4.06 billion, a PE ratio of 46.72 and a beta of 1.98.

Veracyte (NASDAQ:VCYT – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.18. The firm had revenue of $139.07 million for the quarter, compared to analysts’ expectations of $130.36 million. Veracyte had a return on equity of 9.07% and a net margin of 16.25%.The company’s revenue was up 21.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.31 EPS. As a group, equities analysts anticipate that Veracyte, Inc. will post 1.29 EPS for the current fiscal year.

Insider Buying and Selling

In other Veracyte news, insider John Leite sold 13,975 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $50.07, for a total value of $699,728.25. Following the completion of the transaction, the insider owned 132,305 shares of the company’s stock, valued at $6,624,511.35. The trade was a 9.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Jonathan Wygant sold 24,000 shares of the stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $45.40, for a total transaction of $1,089,600.00. Following the completion of the transaction, the chief accounting officer directly owned 45,434 shares in the company, valued at $2,062,703.60. The trade was a 34.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 202,967 shares of company stock valued at $9,881,831 in the last 90 days. 1.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. raised its position in Veracyte by 289.9% during the second quarter. Osaic Holdings Inc. now owns 1,201 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 893 shares in the last quarter. Torren Management LLC purchased a new position in shares of Veracyte in the 4th quarter worth about $37,000. Empowered Funds LLC purchased a new position in shares of Veracyte in the 4th quarter worth about $42,000. Smartleaf Asset Management LLC increased its position in shares of Veracyte by 159.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,104 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 679 shares during the last quarter. Finally, Neo Ivy Capital Management bought a new position in shares of Veracyte during the 3rd quarter valued at about $56,000.

About Veracyte

(Get Free Report)

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.